You are here: Industry Insights > Market News

News List

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon C PR Newswire
February 24, 2025
Innovent's NDA for ipilimumab with sintilimab as neoadjuvant for MSI-H/dMMR colon cancer is accepted and gets Priority Review, based on trial results.
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside PR Newswire
February 24, 2025
AIM Vaccine Co., Ltd. fully deploys DeepSeek large model, promoting its application in vaccine R & D, clinical, production, etc., with growth potential.
3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics PR Newswire
February 24, 2025
3Z Pharmaceuticals publishes a study on ADHD treatments' metabolic mechanisms, revealing key findings and advancing CNS drug discovery.
BioMed X Barbados, a new Research Initiative Focused on better Treatment of Cardiometabolic Diseases in Individuals of African Descent Biotech Newswire
February 20, 2025
A new research initiative focused on better treatment of cardiometabolic diseases in individuals of African descent.
Eleva Appoints Martin Bauer, MD as Chief Medical Officer Adding Substantial Clinical Development Expertise to the Organization Biotech Newswire
February 20, 2025
Eleva appoints Dr. Martin Bauer as CMO. Its Factor H (CPV - 104) program may enter clinic in 2025 for C3G, and dry AMD is a potential second indication.
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
Navi Medical Technologies' Neonav® ECG Tip Location System Receives FDA 510(k) Clearance PR Newswire
February 17, 2025
FDA 510(k) Clearance Revolutionising Vascular Access Care for Critically Ill Newborns and Children
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 in Squamous Non-Small Cell Lung Cancer PR Newswire
February 17, 2025
Innovent Receives FDA for IBI363 in Squamous Non-Small Cell Lung Cancer
Baltics Leading Pharmaceutical Company Grindeks Expands to new Export Markets Worldwide PR Newswire
February 17, 2025
Grindeks Continues to Strengthen its Global Presence by Entering new Export markets.
RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer PR Newswire
February 15, 2025
At 2025 ASCO GU, Prof. Xinan Sheng disclosed phase II trial data of DV + Toripalimab for HER2 - expressing MIBC, showing high pCR and manageable safety.